Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 5 | 2014 | 49 | 1.020 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 156 | 0.930 |
Why?
|
| Head and Neck Neoplasms | 4 | 2015 | 137 | 0.860 |
Why?
|
| Brachytherapy | 7 | 2010 | 29 | 0.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2008 | 442 | 0.830 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 7 | 0.600 |
Why?
|
| Laryngeal Neoplasms | 1 | 2019 | 16 | 0.600 |
Why?
|
| Papillomaviridae | 1 | 2019 | 23 | 0.600 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2015 | 372 | 0.580 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 70 | 0.560 |
Why?
|
| Radiation Injuries | 3 | 2008 | 85 | 0.530 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2007 | 43 | 0.490 |
Why?
|
| Radiotherapy Dosage | 8 | 2015 | 106 | 0.480 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 24 | 0.450 |
Why?
|
| Hysterectomy | 3 | 2009 | 52 | 0.390 |
Why?
|
| Disease-Free Survival | 6 | 2015 | 322 | 0.380 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 458 | 0.360 |
Why?
|
| Radiotherapy | 3 | 2008 | 92 | 0.340 |
Why?
|
| Iodine Radioisotopes | 2 | 2010 | 22 | 0.320 |
Why?
|
| Choroid Neoplasms | 1 | 2010 | 4 | 0.310 |
Why?
|
| Middle Aged | 12 | 2019 | 11843 | 0.300 |
Why?
|
| Pyrazoles | 2 | 2007 | 77 | 0.300 |
Why?
|
| Sulfonamides | 2 | 2007 | 85 | 0.300 |
Why?
|
| Cisplatin | 5 | 2008 | 77 | 0.300 |
Why?
|
| Aged | 10 | 2019 | 10257 | 0.280 |
Why?
|
| Melanoma | 1 | 2010 | 166 | 0.280 |
Why?
|
| Ovariectomy | 1 | 2009 | 202 | 0.280 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2008 | 23 | 0.270 |
Why?
|
| Female | 15 | 2019 | 19954 | 0.270 |
Why?
|
| Deglutition Disorders | 1 | 2008 | 52 | 0.270 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 94 | 0.260 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2014 | 83 | 0.260 |
Why?
|
| Tomography, Emission-Computed | 2 | 2004 | 27 | 0.260 |
Why?
|
| Humans | 21 | 2019 | 32284 | 0.250 |
Why?
|
| Adult | 8 | 2019 | 9263 | 0.250 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 17 | 0.250 |
Why?
|
| Combined Modality Therapy | 5 | 2008 | 550 | 0.250 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 3896 | 0.240 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 5 | 0.230 |
Why?
|
| Pelvis | 1 | 2006 | 67 | 0.220 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 773 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2009 | 185 | 0.180 |
Why?
|
| Paclitaxel | 3 | 2008 | 57 | 0.180 |
Why?
|
| Prognosis | 2 | 2019 | 1529 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Male | 9 | 2019 | 19434 | 0.160 |
Why?
|
| Cell Transformation, Viral | 1 | 2019 | 9 | 0.150 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 61 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2015 | 3612 | 0.150 |
Why?
|
| Risk Factors | 4 | 2008 | 3938 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2008 | 169 | 0.140 |
Why?
|
| CA-125 Antigen | 2 | 2011 | 8 | 0.140 |
Why?
|
| Prostatic Neoplasms | 3 | 2007 | 489 | 0.130 |
Why?
|
| Carcinoma, Adenosquamous | 2 | 2007 | 4 | 0.130 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 84 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2007 | 79 | 0.120 |
Why?
|
| Recurrence | 2 | 2009 | 287 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2008 | 478 | 0.110 |
Why?
|
| Radiation Oncology | 1 | 2014 | 14 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 298 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2010 | 2238 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2009 | 3410 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2008 | 906 | 0.090 |
Why?
|
| Eye Enucleation | 1 | 2010 | 5 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 62 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2010 | 76 | 0.070 |
Why?
|
| Cause of Death | 1 | 2010 | 236 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 470 | 0.070 |
Why?
|
| Carboplatin | 1 | 2008 | 42 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 212 | 0.070 |
Why?
|
| Patient Selection | 1 | 2009 | 272 | 0.070 |
Why?
|
| Time Factors | 2 | 2010 | 2196 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2004 | 49 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 595 | 0.060 |
Why?
|
| Leukopenia | 1 | 2006 | 9 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2007 | 164 | 0.060 |
Why?
|
| Radiopharmaceuticals | 2 | 2004 | 93 | 0.060 |
Why?
|
| Anemia | 1 | 2006 | 50 | 0.060 |
Why?
|
| Radiometry | 1 | 2006 | 52 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2006 | 7 | 0.060 |
Why?
|
| Genitalia | 1 | 2006 | 9 | 0.060 |
Why?
|
| Rectum | 1 | 2006 | 18 | 0.060 |
Why?
|
| Sexuality | 1 | 2006 | 14 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 293 | 0.060 |
Why?
|
| Urogenital System | 1 | 2005 | 11 | 0.060 |
Why?
|
| Urinary Tract | 1 | 2006 | 31 | 0.060 |
Why?
|
| Anal Canal | 1 | 2006 | 34 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2005 | 41 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2006 | 68 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2006 | 91 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 892 | 0.050 |
Why?
|
| Neck Dissection | 1 | 2004 | 11 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 858 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2009 | 1424 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 548 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 222 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2004 | 206 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1299 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 880 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2004 | 394 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2014 | 95 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2006 | 2320 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 312 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 590 | 0.020 |
Why?
|
| Quality of Life | 1 | 2014 | 971 | 0.020 |
Why?
|
| Organ Size | 1 | 2006 | 221 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 69 | 0.010 |
Why?
|
| International Cooperation | 1 | 2004 | 31 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 555 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 1211 | 0.010 |
Why?
|